Varenicline: For smoking cessation

Kathmandu University Medical Journal

Volumn 7, Issue 26, 2009, Pages 162-164

  Rao, J ^a   Shankar, Pinakini K ^b  

^a MELAKA MANIPAL MEDICAL COLLEGE   (India)

^b American University of Antigua   (Guatemala)

Author keywords

Partial agonist; Smoking cessation; Varenicline; 4 2 nicotinic acetylcholine receptor

Indexed keywords

AMFEBUTAMONE; CIMETIDINE; DIGOXIN; METFORMIN; NICOTINE; PLACEBO; VARENICLINE; WARFARIN;

ABNORMAL DREAMING; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DYSGEUSIA; FLATULENCE; HUMAN; INSOMNIA; NAUSEA; NICOTINE REPLACEMENT THERAPY; RECOMMENDED DRUG DOSE; REPEATED DRUG DOSE; REVIEW; REWARD; SINGLE DRUG DOSE; SMOKING; SMOKING CESSATION; SUSTAINED DRUG RELEASE; TOBACCO DEPENDENCE; VOMITING; WITHDRAWAL SYNDROME;

EID: 67649616356     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: 10.3126/kumj.v7i2.2714     Document Type: Review

References (15)

1. Fiore MC, Croyle RT, Curry SJ, Cutler CM, Davis RM, Gordon C, et al. Preventing 3 million deaths and helping 5 million smokers quit: a national action plan for tobacco cessation. American Journal of Public Health. 2004; 94(2):205-210 (Pubitemid 38176311)
2. Henningfield JE, Fant RV, Buchhalter AR, Stitzer ML. CA Pharmacotherapy for nicotine dependence. Cancer J Clin. 2005; 55(5):281-299 (Pubitemid 41377333)
3. Wu P, Wilson K, Dimoulas P, Mills EJ. Effectiveness of smoking cessation therapies: A systematic review and meta-analysis. BMC Public Health. 2006;11(6):300-306
4. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004:CD000146.
5. Mihalak KB, Carroll FI, Luetje CW. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors. Mol Pharmacol. 2006; 70(3):801-805 (Pubitemid 44268437)
6. Tonstad S. Varenicline for smoking cessation. Expert Rev Neurother. 2007; 7(2):121-127 (Pubitemid 46434162)
7. Keating GM, Siddiqui MA. Varenicline: a review of its use as an aid to smoking cessation therapy. CNS Drugs. 2006; 20(11):945-960 (Pubitemid 44611142)
8. Burstein HA, Fullerton T, Clark JD, and Faessel HM. Pharmacokinetics, Safety, and Tolerability After Single and Multiple Oral Doses of Varenicline in Elderly Smokers. J of Clinic Pharmacol. 2006; 46:1234-1240
9. Orbach RS, Reed-Hagen AE, Krueger SS, et al. Metabolism and disposition of varenicline, a selective α4β2 acetylcholine receptor partial agonist, in vivo and in vitro. Drug Metab Dispos. 2006; 34:121-130 (Pubitemid 43042653)
10. Faessel HM, Gibbs MA, Clark DJ, Rohrbacher K, Stolar M, Burstein AH. Multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers. J Clin Pharmacol. 2006 Dec;46(12):1439-1448 (Pubitemid 44704204)
11. Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006;166:1571-1577 (Pubitemid 44232364)
12. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006; 296:47-51.
13. Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006; 296:56-63.
14. Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006; 296:64-71.
15. Nides MCO, Gonzales D, Rennard SI, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion controlled trial with 1-year follow-up. Arch Intern Med 2006; 166:1561-1568 (Pubitemid 44232363)